// App-Quantinova.ai

TPS9111 : A phase 1b trial of ROR agonist LYC-55716 in combination with pembrolizumab to evaluate safety, efficacy, and immune biomarker profiles in patients with metastatic non-small cell lung cancer.

Researchers

Presenter

  • D. Ross Camidge

Principal Investigators

  • Shirish M. Gadgeel

  • Garry Alan Weems

  • H. Jeffrey Wilkins

  • Melissa Lynne Johnson

Medical Centers

  • University of Colorado Cancer Center, Aurora, CO

  • University of Michigan, Ann Arbor, MI

  • Lycera Corp., Plymouth Meeting, PA

  • Sarah Cannon Research Institute, Nashville, TN

Locations

  • United States

Companies

  • Lycera Corp.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Cohort

Phase

  • NA

Study Id's

  • NCT0336497

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved